SELİM SEKKİN, CAVİT KUM, ŞÜKRÜ KIRKAN, ÖZAY GÜLEŞ, FERDA AKAR

The efficacy of a cefoperazone - danofloxacin combination in the treatment of subclinical mastitis in dairy cows caused by Staphylococcus aureus

Sütçü ineklerde S. aureus’un neden olduğu subklinik mastitiste meme içi tek doz uygulanan sefoperazon ve danofloksasin kombinasyonunun (CDC) etkinliği bu çalışmada araştırıldı. CDC etkinliği in vitro olarak S. aureus’a karşı checkerboard testiyle kanıtlandı. Mastitisin varlığı 223 sağım dönemindeki ineğin 892 meme bölümünde bakteri kültürü ve doğrudan mikroskopik somatik hücre sayımı (SCC) ile belirlendi, rastgele seçilen 22 inek (32 meme bölümü) sağaltım grubu ve 11 inek (15 meme bölümü) kontrol grubu olarak ayrıldı. Denemeden 1 hafta önce ve sağaltımın 0, 14, 21 ve 28. günlerinde süt örnekleri alındı. Sağaltıma alınana meme bölümlerinde bakteriyolojik iyileşme incelendi. Bakteriyolojik iyileşme daha önce saptanan S. aureus’un sağaltım sonrası saptanmaması olarak kabul edildi. Sağaltım grubunda SCC sağaltımın 4. haftasında değişmeden kaldı, iyileşen meme bölümlerinde (kendiliğinden veya CDC uygulanan) denemenin 21. ve 28. günlerinde anlamlı farklılık vardı (P

Anahtar Kelimeler:

Staphylococcus aureus, antibakteriyel ajanlar, sefoperozon, süt ineği, ilaç kombinasyonları, ilaç tedavisi, meme yangısı, subklinik meme yangısı

Sütçü ineklerde S. aureus'un neden olduğu subklinik mastitisin sağaltımında sefoperazon - danofloksasin kombinasyonunun etkinliği

We report on the effectiveness and profitability of a single-dose intramammary administration of cefoperazone and danofloxacin combination (CDC) against subclinical mastitis in lactating cows. The CDC proved to be effective against Staphylococcus aureus (S. aureus), in vitro checkerboard trials. The presence of mastitis examined on the 892 mammary quarters of 223 lactating cows by bacterial cultures and microscopic somatic cell counting (SCC). Selecting the subjects at random from the 223 animals, twenty-two cows (32 quarters) used for treatment and eleven cows (15 quarters) as controls. Milk samples received one week before the start of treatment and on days 0, 14, 21 and 28 of the experiment. Bacteriological cure examined to the treated quarters. Bacteriological cure defined as no signs of S. aureus after treatment of quarters previously confirmed as infected. The SCC remained unchanged 4 weeks after treatment started, but quarters that were cured (spontaneously or by CDC) showed significant differences on days 21 and 28 (P<0.05). There was no S. aureus in 53.1% of the treated quarters with intramammary CDC, while in the controls there was spontaneous cure of the infection in 13.3% of the untreated quarters with significant (P<0.05) difference. These preliminary results suggest the intramammary application of CDC is an effective and profitable therapy in treating S. aureus infection resulting in subclinical mastitis in lactating cows..

Keywords:

Staphylococcus aureus, antibacterial agents, cefoperazone, dairy cows, drug combinations, drug therapy, mastitis, subclinical mastitis,

PDF

___

1. Kaya İ, Güven A: Mastitisli ineklerde kan vitamin A, βkaroten ve vitamin E düzeylerinin belirlenmesi. Kafkas Üniv Vet Fak Derg, 14, 57-61, 2008.
2. Halasa T, Huijps K, Osteras O, Hogeveen H: Economic effects of bovine mastitis and mastitis management: A review. Vet Q, 29, 18-31, 2007.
3. Yağcl İP: Koyunlarda subklinik mastitis: Etiyoloji, epidemiyoloji ve tanı yöntemleri. Kafkas Üniv Vet Fak Derg, 14: 117-122, 2008.
4. Owens WE, Nickerson SC, Boddie RL, Tomita GM, Ray CH: Prevalence of mastitis in dairy heifers and effectiveness of antibiotic therapy. J Dairy Sci, 84, 814-817, 2001.
5. Erskine RJ, Wagner S, DeGraves FJ: Mastitis therapy and pharmacology. Vet Clin North Am: Food Anim Pract, 19, 109-138, 2003.
6. Pyorala S, Pyorala E: Accuracy of methods using somatic cell count and N-acetyl-beta-D-glucosaminidase activity in milk to assess the bacteriological cure of bovine clinical mastitis. J Dairy Sci, 80, 2820-2825, 1997.
7. Sol J, Sampimon OC, Barkema HW, Schukken YH: Factors associated with cure after therapy of clinical mastitis caused by Staphylococcus aureus. J Dairy Sci, 83, 278-284, 2000.
8. Guler L, Ok U, Gunduz K, Gulcu Y, Hadimli HH: Antimicrobial susceptibility and coagulase gene typing of Staphylococcus aureus isolated from bovine clinical mastitis cases in Turkey. J Dairy Sci, 88, 3149-3154, 2005.
9. Pyorala S: New strategies to prevent mastitis. Reprod Domest Anim, 37, 211-216, 2002.
10. Sears PM, McCarthy KK: Management and treatment of staphylococcal mastitis. Vet Clin North Am: Food Anim Pract, 19, 171-185, 2003.
11. Barkema HW, Schukken YH, Zadoks RN: Invited review: The role of cow, pathogen, and treatment regimen in the therapeutic success of bovine Staphylococcus aureus mastitis. J Dairy Sci, 89, 1877-1895, 2006.
12. Sol J, Sampimon OC, Snoep JJ, Schukken YH: Factors associated with bacteriological cure during lactation after therapy for subclinical mastitis caused by Staphylococcus aureus. J Dairy Sci, 80, 2803-2808, 1997.
13. Sol J, Sampinon OC, Snoep J: Results of treatment subclinical Staphylococcus aureus mastitis during lactation. Proceedings of the Third IDF International Mastitis Seminar. Tel-Aviv, Israel, 68-72, 1995.
14. Sandholm M, Kaartinen L, Pyorala S: Bovine mastitis why does antibiotic therapy not always work? An overview. J Vet Pharmacol Ther, 13, 248-260, 1990.
15. Eliopoulos GM, Moellering RC: Antimicrobial Combinations. In, Lorian V (Ed): Antibiotics in Laboratory Medicine 4th ed. pp. 330-396, Williams & Wilkins, Maryland, 1996.
16. Neu HC: Synergy of flouroquinolones with other antimicrobial agents. Rev Infect Dis, 11, 1025-1033, 1989.
17. Swinkels JM, Hogeveen H, Zadoks RN: A partial budget model to estimate economic benefits of lactational treatment of subclinical Staphylococcus aureus mastitis. J Dairy Sci, 88, 4273-4287, 2005.
18. Lehenbauer TW, Oltjen JW: Dairy cow culling strategies: Making economical culling decisions. J Dairy Sci, 81, 264271, 1998.
19. Serieys F, Raguet Y, Goby L, Schmidt H, Friton G: Comparative efficacy of local and systemic antibiotic treatment in lactating cows with clinical mastitis. J Dairy Sci, 88, 93-99, 2005.
20. Gillespie BE, Moorehead H, Lunn P, Dowlen HH, Johnson DL, Lamar KC, Lewis MJ, Ivey SJ, Hallberg JW, Chester ST, Oliver SP: Efficacy of extended pirlimycin hydrochloride therapy for treatment of environmental Streptococcus spp. and Staphylococcus aureus intramammary infections in lactating dairy cows. Vet Ther, 3, 373-380, 2002.
21. Oliver SP, Gillespie BE, Headrick SJ, Moorehead H, Lunn P, Dowlen HH, Johnson DL, Lamar KC, Chester ST, Moseley WM: Efficacy of extended ceftiofur intramammary therapy for treatment of subclinical mastitis in lactating dairy cows. J Dairy Sci, 87, 2393-2400, 2004.
22. Wilson DJ, Gonzalez RN, Case KL, Garrison LL, Grohn YT: Comparison of seven antibiotic treatments with no treatment for bacteriological efficacy against bovine mastitis pathogens. J Dairy Sci, 82, 1664-1670, 1999.
23. Gruet P, Maincent P, Berthelot X, Kaltsatos V: Bovine mastitis and intramammary drug delivery: Review and perspectives. Adv Drug Deliv Rev, 50, 245-259, 2001.
24. Mainardi JL: Associations d’antibiotiques pour le traitement des infections à Staphylococcus aureus. Med Mal Infect, 27, 217- 224, 1997.
25. Neu HC: Synergy and antagonism of combination with quinolones - Review. Eur J Clin Microbiol, 10, 255-261, 1991.
26. Shem-Tov M, Rav-Hon O, Ziv G, Lavi E, Glickman A, Saran A: Pharmacokinetics and penetration of danofloxacin from blood into the milk of cows. J Vet Pharmacol Ther, 21, 209-213, 1998.
27. Wilson CD, Gilbert GA: Pharmacokinetics of cefoperazone in the cow by the intramammary route and its effect on mastitis pathogens in vitro. Vet Rec, 118, 607-609, 1986.
28. Dong-Min K, Yong L, Sook JJ, Hulin H, Young GK, Choon-Hae C, Soon PH: In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus. Antimicrob Agents Chemother, 49, 3489-3491, 2005.
29. Douglas NF, Micahael KC, Rose J: Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother, 50, 1045-1049, 2002.
30. Mayer I, Nagy E: Investigation of the synergic effects of aminoglycoside- fluoroquinolone and third - generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother, 43, 651-657, 1999.
31. Moody JA, Gerding DN, Peterson LR: Evaluation of ciprofloxacin’s synergism with other agents by multiple in vitro methods. Am J Med, 82, 44-54, 1987.
32. Wilson CD, Agger N, Gilbert GA, Thomasson CA, Tolling ST: Field trials with cefoperazone in the treatment of bovine clinical mastitis. Vet Rec, 118, 17-19, 1986.
33. Shem-Tov M, Ziv G, Glickman A, Saran A, Bor A: Penetration of marbofloxacin and danofloxacin from blood into the milk of lactating ewes after intravenous and intramuscular administration. Proceedings of the Third IDF International Mastitis Seminar, Tel-Aviv, Israel, pp. 132-133, 1995.
34. Williams AC, Barry BW: Penetration enhancers. Adv Drug Deliv Rev, 56, 603-618, 2004.
35. Magnusson BM, Walters KA, Roberts MS: Veterinary drug delivery: Potential for skin penetration enhancement. Adv Drug Deliv Rev, 50, 205-227, 2001.
36. Schalm OW, Carrol EJ, Jain NC: Bovine Mastitis. Lea and Febiger, Philadelphia, 1971.
37. Holt JG, Krieg NR, Sneath PHA, Staley JT, Williams ST: Gram-positive cocci. Bergey’s Manual of Determinative Bacteriology, 9th ed. Group 17, Willams & Wilkins, Maryland, 1994.
38. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC: The Gram-Positive Cocci. In, Color Atlas and Textbook of Diagnostic Microbiology. 5th ed. Lippincott-Raven Publishers, Philadelphia, 1997.
39. NCCLS (National Committee for Clinical Laboratory Standards): Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Approved standard. 2nd ed. NCCLS, Wayne, 2002.
40. Sekkin S, Şanlı Y: İneklerde mastitis sağaltımı için etkili bir antibakteriyel ilaç kombinasyonu (sefalosporinler ve florokinolonlar) üzerinde çallşmalar. Süt İnekçiliğinde Mastitis Sempozyumu, s. 102-112, Burdur, 2001.
41. Kirkan S, Goksoy EO, Kaya O: Identification and antimicrobial susceptibility of Staphylococcus aureus and coagulase negative Staphylococci from bovine mastitis in the Aydin region of Turkey. Turk J Vet Anim Sci, 29, 791-796, 2005.
42. Owens WE, Ray CH, Watts JL, Yancey RJ: Comparison of success of antibiotic therapy during lactation and results of antimicrobial susceptibility tests for bovine mastitis. J Dairy Sci, 80, 313-317, 1997.
43. Nickerson SC, Owens WE: Staphylococcus aureus mastitis: Reasons for treatment failures and therapeutic approaches for control. Agri-Practice, 14, 18-23, 1993.
44. Owens WE, Nickerson SC, Ray CH: Efficacy of parenterally or intramammarily administered tilmicosin or ceftiofur against Staphylococcus aureus mastitis during lactation. J Dairy Sci, 82, 645-647, 1999.
45. Nickerson SC: Clinical mastitis: To treat or not to treat? Proceedings of the Western Canadian Dairy Seminar. http://www.wcds.afns.ualberta.ca/Proceedings/1996/wcd9635 5.htm Accessed: 24 March 2008.
46. Schukken YH, Wilson DJ, Welcome F, Garrison-Tikofsky L, Gonzales RN: Monitoring udder health and milk quality using somatic cell counts. Vet Res, 34, 579-596, 2003.
47. Nickerson SC: Control of heifer mastitis: Antimicrobial treatment - an overview. Vet Microbiol, 134, 128-135, 2009.
48. Deluyker HA, Van Oye SN, Boucher JF: Factors affecting cure and somatic cell count after pirlimycin treatment of subclinical mastitis in lactating cows. J Dairy Sci, 88, 604614, 2005.
49. Bradley AJ, Green MJ: Factors affecting cure when treating bovine clinical mastitis with cephalosporin based intramammary preparations. J Dairy Sci, 92, 1941-1953, 2009.
50. Sandragen CH, Waller, KP, Emanuelson U: Therapeutic effects of systemic or intramammary antimicrobial treatment of bovine subclinical mastitis during lactation. Vet J, 175, 108-117, 2008.